Geron inks stem-cell deal with GE Healthcare - San Francisco Business Times:

hustbelogehy1857.blogspot.com
The products developed should allow researchers to spot toxicityu problems with drug candidates earlier in the drug development Earlier detection of toxicity problems in the labrather than, more harmfully, in humanb testing — could reduce both overall drug developmentr costs and potential harm to people. GE Healthcaree will fund the research and development program and will be responsible for sales and distribution of the Thecompanies didn’t give financial The work will use stem cells derivedc from human embryonic stem cell (hESC) lines listes on the National Institutes of Healtnh Human Pluripotent Stem Cell Registry, which are eligiblew for federal funding.
GE Healthcare gets an exclusivw licenseunder Geron’s intellectual propertg portfolio covering the growth and differentiation of hESCs, as well as a sublicensw under Geron’s rights to the foundational hESC patentz held by the Wisconsij Alumni Research Foundation, the patent licensintg arm of the . The firsty products developed under this deal shoulfd be available by early with a pipeline of productdto follow. Under the terms of the intellectual property rights arising from the alliancs program research will be with GE Healthcare receivinfg rights for the development of drug discovery and Geron receiving rights for celltherapuy applications.
GE Healthcare, a unit of Fairfield, Conn.-based Generakl Electric Co. (NYSE: GE), is basexd in the United Kingdom. Geron (NASDAQ: is based in Menlo Park.